Novo Nordisk: Yahoo Finance's Company of the Year, 2023
Novo Nordisk (NVO) and more specifically its blockbuster weight-loss drugs Ozempic and Wagovy have been the topic of many conversations across Wall Street and well beyond this year, due to the comp...
Why Novo Nordisk's corporate structure stands out
Yahoo Finance selected Novo Nordisk (NVO) as its Company of the Year for 2023, and there are plenty of reasons why. One interesting reason some investors may not know about, however, is its unique ...
Novo Nordisk: From diabetes to weight loss to obesity preventions
Having developed a blockbuster diabetes treatment that has gained huge traction in the weight loss market, Novo Nordisk (NYSE:NVO) is now expanding its focus to include the prevention of obesity, a...
Everyone Is Talking About This Stock. Is It a Good Long-Term Option?
Novo Nordisk's weight-loss products soared in popularity this year. The company remains a leader in this area thanks to its innovations.
Will Novo Nordisk Be a Trillion-Dollar Stock by 2030?
Novo Nordisk is a big name in diabetes and obesity care. Both Wegovy and Ozempic are fast-growing drugs with a ton of upside.
Novo Nordisk sues two pharmacies for allegedly selling tainted Wegovy, Ozempic knockoffs
The lawsuits come as Novo Nordisk grapples with shortages of Wegovy and Ozempic in the U.S. due to skyrocketing demand.
Novo Nordisk Sues Two Florida Pharmacies For Allegedly Selling Impure Weight-Loss Drugs
The Danish drugmaker claims one pharmacy is adding a banned substance to its drugs.
Novo Nordisk finds compounded Wegovy up to 33% impure, sues Florida pharmacies
Novo Nordisk on Thursday said it sued one compounding pharmacy and refiled a lawsuit against another after finding their products claiming to contain the active ingredient for its in-demand weight-...
Ozempic Receives Some Very Bad News: Is It Time to Sell Novo Nordisk Stock?
New real-world data show that Lilly's Mounjaro helped patients achieve significantly greater weight loss than Ozempic did. This demonstration of Mounjaro's efficacy could lead to a shift in prescri...
Ozempic is not the most effective weight-loss drug on the market: study
Diabetes-turned-weight loss drug Mounjaro is more effective for shedding off extra pounds than its ultra-popular counterpart, Ozempic, according to a new study.
Novo Nordisk: Healthy Gains Ahead, EPS Growth Seen, Technical Strength
Novo Nordisk has surpassed Nestle as the largest developed-market stock outside of the US, indicating the success of the GLP-1 drug segment. The company had a strong Q3 with a 29% YoY increase in r...
New Highs: Novo Nordisk, PGT Innovations Among Best Stocks To Buy Now
Novo Nordisk and PGT Innovations continue to show relative strength and are among the best stocks to buy now.
Novo Nordisk (NVO) to Expand Manufacturing Site in France
Novo Nordisk (NVO) announces that it is initiating plans to expand its existing manufacturing facility in Chartres, France, for the current and future product portfolio within serious chronic disea...
Pharma Stock Hits Record High After Expansion Plans
Pharmaceutical name Novo Nordisk A/S (NYSE:NVO) is up 1.6% at $104.93 at last glance, earlier hitting a fresh record peak of $105.30.
Novo Nordisk to invest $2 billion in France production boost
Weight loss drug developer Novo Nordisk (NYSE:NVO) has announced US$2.3 billion will be spent on ramping up production in France. Set to boost capacity, quality control lab space, aseptic and finis...
Related Companies